Contents
- 1 Citation, commencement and interpretation
- 2 Appropriate practitioners
- 3 Medicinal products on prescription only
- 3A Prescribing and administration by nurse independent prescribers
- 3B Prescribing and administration by supplementary prescribers
- 3C Exemptions from conditions in respect of the cases or circumstances in which a supplementary prescriber may administer a medicinal product
- 4 Duration of special provisions in relation to new medicinal products
- 5 Exempt medicinal products
- 5A Exemption for products consisting of or containing aloxiprin, aspirin or paracetamol
- 5B Exemption for products consisting of or containing pseudoephedrine salts or ephedrine base or salts
- 6 Circumstances in which controlled drugs and medicinal products authorized by the European Community are not prescription only medicines
- 7 Exemption for parenteral administration in an emergency to human beings of certain prescription only medicines
- 7A Exemptions for administration of smallpox vaccine
- 7B Exemption for administration by operators
- 8 Exemptions for emergency sale or supply
- 9 Exemption for non-parenteral administration to human beings
- 10 Exemption for medicinal products at high dilutions
- 11 Exemptions for certain persons
- 12 Exemption for sale or supply in hospitals
- 12A Exemptions for the supply and administration of prescription only medicines by national health service bodies
- 12B Exemption for health professionals who supply or administer prescription only medicines under a Patient Group Direction in order to assist doctors or dentists in providing national health services
- 12C Exemption for persons conducting a retail pharmacy business who supply or administer prescription only medicines under a Patient Group Direction
- 12D Exemption for the supply and administration of prescription only medicines by independent hospitals, clinics and agencies
- 12E Exemption for health professionals who supply or administer prescription only medicines under a Patient Group Direction in order to assist the provision of health care by or on behalf of the police, the prison services or the armed forces
- 12F Exemption for the supply of prescription only medicines in the event or anticipation of pandemic disease
- 13 Exemption in cases involving another’s default
- 13A Exemptions relating to prescriptions given by certain health professionals
- 14 Exemption in the case of a forged prescription
- 15 Prescriptions
- 16 Revocations
- Schedule 1 Substances which if included in medicinal products make those products prescription only medicines and exemptions from restrictions on the sale and supply of prescription only medicines
- Schedule 2 Substances which may be excluded from the class of prescription only medicines at high dilution
- Schedule 3 DESCRIPTIONS AND CLASSES OF PRESCRIPTION ONLY MEDICINES IN RELATION TO WHICH community practitioner nurse prescribers ARE APPROPRIATE PRACTITIONERS
- Schedule 3A Controlled drugs which may be prescribed, administered or directed for administration by nurse independent prescribers and conditions for such prescription or administration
- Schedule 3B Particulars for clinical management plans
- Schedule 4 Substances not to be contained in a prescription only medicine sold or supplied under the exemption conferred by article 8(3)
- Schedule 5 Exemption for certain persons from section 58(2) of the act
- Schedule 6 Orders revoked
- Schedule 7
Article 1Citation, commencement and interpretation#
(1)This Order may be cited as the Prescription Only Medicines (Human Use) Order 1997 and shall come into force on 18th August 1997.
(2)In this Order, unless the context otherwise requires–• note...• note... • note...• note...• note... • note...• note...• note...• note...• note...• note...• note...• note...• note...• note...• note...• note...• note...• note...• note...• note...• note...• note...• note...• note...• note...• note...• note...• “inhaler” does not include an aerosol;• note...• note...• note...• note...• note...• note...• “maximum strength” means–(a) the maximum quantity of a substance by weight or volume contained in a dosage unit of a medicinal product;(b) the maximum percentage of a substance contained in a medicinal product calculated in any of the following ways–(a) weight in weight,(ii) weight in volume,(iii) volume in weight, or(iv) volume in volume,and if the maximum percentage calculated in those ways differs, the higher or highest such percentage;• note...• note...• note...• note...• note...• note...• note...• note...• note...• note...• note...• note...• note...• note...• note...• note...• note...• note...• note...• note...• note...• note...• note...• note...• note...• note...• note...• note...• note...• note...• note...• note...• note...• note...• note...• note...• note...• note...• note...• note...• note...• note...• note...• note...• note...• note...
(2A)In this Order, unless the context otherwise requires, any expression defined by any provision of the Human Medicines Regulations 2012 has the same meaning as it has for the purposes of those Regulations.
(3)For the purposes of this Order, the equivalence of a substance to a reference material shall be determined by calculating the amount of that reference material which is contained in that substance either by weight or, where the amount of the reference material is specified in terms of international units of activity, those units.
(4)In this Order, unless the context otherwise requires, a reference–
(a)to a numbered section is to the section of the Act which bears that number,
(b)to a numbered article or Schedule is to the article of, or Schedule to, this Order which bears that number,
(c)in an article or in a Part of a Schedule to a numbered paragraph is to the paragraph of that article or Part of that Schedule which bears that number, and
(d)in a paragraph to a lettered sub-paragraph is to the sub-paragraph of that paragraph which bears that letter.
(5)In Schedules 1 and 2–
(a)entries specified in columns 2 to 5 relate to the substances listed in column 1 against which they appear and where, in relation to a particular substance listed in column 1, an entry in columns 2 to 5 bears a number or letter it relates only to such entries in the other of those columns as bear the same number or letter;
(b)the following abbreviations are used:• “g” for gram,• “iu” for international unit of activity,• “mcg” for microgram,• “mg” for milligram,• “ml” for millilitre.
(6). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
(7). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
(8). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
(9). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Article 3Medicinal products on prescription only#
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Article 3APrescribing and administration by nurse independent prescribers#
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Article 3BPrescribing and administration by supplementary prescribers#
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Article 3CExemptions from conditions in respect of the cases or circumstances in which a supplementary prescriber may administer a medicinal product#
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Article 4Duration of special provisions in relation to new medicinal products#
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Article 5Exempt medicinal products#
(1)A medicinal product that is not the subject of a marketing authorisation is a prescription only medicine for the purposes of the Human Medicines Regulations 2012 if it, or a substance in it, is listed in column 1 of Schedule 1, unless there –
(a)is an entry in column 2, 3, 4 or 5 of that Schedule which contains a condition and that condition is satisfied in accordance with the following provisions of this article; or
(b)there is more than one such condition which applies where that substance is used in that product and each of those conditions is so satisfied.
(1A)In paragraph (1) “marketing authorisation” means—
(a)in relation to medicinal products for sale or supply in Great Britain, a UKMA(GB) or UKMA(UK);
(b)in relation to medicinal products for sale or supply in Northern Ireland, a UKMA(NI) or UKMA(UK), an EU marketing authorisation or a parallel import licence.
(2)Where a maximum strength is specified in column 2 in relation to a substance, a medicinal product which consists of or contains that substance satisfies the condition where the maximum strength of that substance in that medicinal product, or where specified in that column the maximum strength of a medicinal product which contains that substance, does not exceed that specified maximum or, where the medicinal product consists of more than one of the substances sodium fluoride, sodium monofluorophosphate or stannous fluoride combined in a dentifrice, where the maximum strength of that combination of substances in a product does not exceed the equivalent of 0.15 per cent of fluorine.
(3)Where a route of administration is specified in column 3 in relation to a substance, a medicinal product which consists of or contains that substance satisfies the condition where it is sold or supplied for administration only by that route.
(4)Where a use is specified in column 3 in relation to a substance, a medicinal product which consists of or contains that substance satisfies the condition in respect of use where it is sold or supplied only for use–
(a)where a purpose for which it may be used is so specified, for that purpose;
(b)where the class of persons in whom it may be used is so specified, in persons of that class ,
provided that, where the entry in column 3 contains a condition to the effect that the product is to be wholly or mainly for use in a specified class of persons, the product satisfies that condition where it is sold or supplied wholly or mainly for use in persons of that class.
(5)Where a pharmaceutical form is specified in column 3 in relation to a substance, a medicinal product which consists of or contains that substance satisfies the condition where it is sold or supplied in that pharmaceutical form.
(6)Where a maximum dose is specified in column 4 in relation to a substance, a medicinal product which consists of or contains that substance satisfies the condition where it is sold or supplied for use at a maximum dose which does not exceed that specified maximum dose.
(7)Subject to paragraph (8), where a maximum daily dose is specified in column 4 in relation to a substance, a medicinal product which consists of or contains that substance satisfies the condition where it is sold or supplied for use at a maximum daily dose which does not exceed that specified maximum daily dose.
(8)A medicinal product which contains more than one of the substances–• Atropine• Atropine Methobromide• Atropine Methonitrate• Atropine Oxide Hydrochloride• Atropine Sulphate• Hyoscine• Hyoscine Butylbromide• Hyoscine Hydrobromide• Hyoscine Methobromide• Hyoscine Methonitrate• Hyoscyamine• Hyoscyamine Hydrobromide• Hyoscyamine Sulphate,satisfies the condition only where it is sold or supplied for use at a maximum daily dose which does not exceed 1 milligram in total of the alkaloids derived from belladonna, hyoscyamus, stramonium or other solanaceous plant which are contained in that medicinal product.
(9)Where a maximum period of use or a maximum frequency of use is specified in column 4 in relation to a substance, a medicinal product which consists of or contains that substance satisfies the condition where it is sold or supplied for use for a maximum period or frequency, as the case may be, which does not exceed the maximum period of use or the maximum frequency of use which is so specified.
(10)Where a maximum quantity is specified in column 5 in relation to a substance, a medicinal product which consists of or contains that substance satisfies the condition where it, or where so specified in that column, the medicinal product which contains that substance is sold or supplied in a quantity which does not exceed that specified maximum quantity.
(11)In paragraphs (2) to (7) and (9) and (10) a reference to a numbered column is a reference to the column bearing that number in Schedule 1.
Article 5AExemption for products consisting of or containing aloxiprin, aspirin or paracetamol#
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Article 5BExemption for products consisting of or containing pseudoephedrine salts or ephedrine base or salts#
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Article 6Circumstances in which controlled drugs and medicinal products authorized by the European Community are not prescription only medicines#
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Article 7Exemption for parenteral administration in an emergency to human beings of certain prescription only medicines#
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Article 7AExemptions for administration of smallpox vaccine#
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Article 7BExemption for administration by operators#
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Article 8Exemptions for emergency sale or supply#
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Article 9Exemption for non-parenteral administration to human beings#
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Article 10Exemption for medicinal products at high dilutions#
(1)A medicinal product is not a prescription only medicine for the purposes of the Human Medicines Regulations 2012 by virtue of Article 5(1) if it is a medicinal product which is not for parenteral administration and which consists of or contains, any of the substances listed in column 1 of Schedule 1 or in Schedule 2, only one or more unit preparation of such substances, if–
(a)each such unit preparation has been diluted to at least one part in a million (6x), and the person selling, supplying or administering the medicinal product has been requested by or on behalf of a particular person and in that person’s presence to use his own judgment as to the treatment required; or
(b)each such unit preparation has been diluted to at least one part in a million million (6c).
(2)A medicinal product is not a prescription only medicine for the purposes of the Human Medicines Regulations 2012 by virtue of Article 5(1) if it is a medicinal product which is not for parenteral administration and which consists of or contains solely one or more unit preparations of the following substances—• Aconite• Arsenic Trioxide• Belladonna Herb• Ignatia Bean• Nux Vomica Seed,if each such unit preparation has been diluted to at least one part in a million (6x)
Article 11Exemptions for certain persons#
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Article 12Exemption for sale or supply in hospitals#
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Article 12AExemptions for the supply and administration of prescription only medicines by national health service bodies#
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Article 12BExemption for health professionals who supply or administer prescription only medicines under a Patient Group Direction in order to assist doctors or dentists in providing national health services#
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Article 12CExemption for persons conducting a retail pharmacy business who supply or administer prescription only medicines under a Patient Group Direction#
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Article 12DExemption for the supply and administration of prescription only medicines by independent hospitals, clinics and agencies#
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Article 12EExemption for health professionals who supply or administer prescription only medicines under a Patient Group Direction in order to assist the provision of health care by or on behalf of the police, the prison services or the armed forces#
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Article 12FExemption for the supply of prescription only medicines in the event or anticipation of pandemic disease#
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Article 13Exemption in cases involving another’s default#
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Article 13AExemptions relating to prescriptions given by certain health professionals#
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Article 14Exemption in the case of a forged prescription#
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Article 15Prescriptions#
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Article 16Revocations#
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Schedule 1 · Substances which if included in medicinal products make those products prescription only medicines and exemptions from restrictions on the sale and supply of prescription only medicines
Schedule 2 · Substances which may be excluded from the class of prescription only medicines at high dilution
Schedule 3 · DESCRIPTIONS AND CLASSES OF PRESCRIPTION ONLY MEDICINES IN RELATION TO WHICH community practitioner nurse prescribers ARE APPROPRIATE PRACTITIONERS
Schedule 3A · Controlled drugs which may be prescribed, administered or directed for administration by nurse independent prescribers and conditions for such prescription or administration
Schedule 3B · Particulars for clinical management plans
Schedule 4 · Substances not to be contained in a prescription only medicine sold or supplied under the exemption conferred by article 8(3)
Schedule 5 · Exemption for certain persons from section 58(2) of the act
Part I · Exemption from restrictions on sale or supply
Part II · Exemptions from the restriction on supply
Part III · EXEMPTIONS FROM RESTRICTION ON ADMINISTRATION Column 1
Schedule 6 · Orders revoked
Schedule 7
Part I
Part II
Part iia
Part III
Contains public sector information licensed under the Open Government Licence v3.0.